th The 8 Engadin Prostate Cancer Winter Symposium Zuoz 27. Feb. – 01. March 2014 www.engadin-symposium.ch SCREENING pro and contra THERAPY XGEVA®: DER ERSTE UND EINZIGE RANK-LIGAND-INHIBITOR ZUR PRÄVENTION VON SRE* The 8th Engadin Prostate Cancer Winter Symposium Zuoz 27. Feb – 01. March 2014 Dear colleagues and friends of this meeting, XGEVA® 120 mg wird einmal alle 4 Wochen als subkutane Injektion gegeben2 It is a great pleasure for me to invite you for the 8th time to our Engadin Prostate Cancer Winter Symposium. One of the most disputed topics at the moment is screening for prostate cancer. Is it justifiable and if, how to do it in optimal way? An individual approach for every single patient is clearly needed. We are also confronted with a number of developments in diagnosis and treatment of prostate cancer. Still the important questions remain: How to inform about prostate cancer risk and how to treat the individual patient? Is active surveillance a justifiable option? How to deal with high risk PCa and with recurrent disease if primary treatment fails? What is the optimal treatment sequence in advanced prostate cancer? * XGEVA® ist indiziert zur Behandlung von Patienten mit Knochenmetastasen solider Tumoren in Verbindung mit einer antineoplastischen Standardtherapie. SRE = Skeletal-related events 1. Lipton A, Siena S, Rader M, et al. Comparison of denosumab versus zoledronic acid (ZA) for treatments of bone metastases in advanced cancer patients: An integrated analysis of 3 pivotal trials. Annals of Oncology. 2010; 21(suppl 8): viii380. Abstract 1249P and poster presentation. Kurzfachinformation XGEVA® (Denosumab): Mittels rekombinanter DNA-Technologie hergestellter humaner monoklonaler IgG2Antikörper. Indikation: Zur Behandlung von Patienten mit Knochenmetastasen solider Tumoren in Verbindung mit einer antineoplastischen Standardtherapie. Dosierung/Anwendung: 120 mg einmal alle 4 Wochen, als einzelne subkutane Injektion. Kontraindikationen: Überempfindlichkeit gegenüber dem Wirkstoff oder einem der Hilfsstoffe. Warnhinweise und Vorsichtsmassnahmen: Patienten sollten nicht gleichzeitig mit Prolia® (enthält ebenfalls Denosumab) behandelt werden. Eine vorbestehende Hypokalzämie muss vor Beginn der Behandlung mit XGEVA® korrigiert werden. Eine Supplementation von Kalzium und Vitamin D ist bei allen Patienten notwendig, ausser bei Hyperkalzämie. Es wird empfohlen, den Kalziumspiegel bei allen Patienten zu überwachen. Osteonekrose im Kieferbereich trat bei Patienten auf, die mit Denosumab behandelt wurden. In klinischen Studien wurden Hautinfektionen (hauptsächlich bakterielle Entzündung des Unterhautgewebes) beobachtet, die zu einer Hospitalisation führten. Patienten mit seltener hereditärer Fructoseintoleranz sollten XGEVA® nicht anwenden. Interaktionen: keine bekannt. Unerwünschte Wirkungen: Sehr häufig: Dyspnoe, Diarrhoe. Häufig: übermässiges Schwitzen, Osteonekrose im Kieferbereich, Hypokalzämie, Hypophosphatämie. Gelegentlich: bakterielle Entzündung des Unterhautgewebes, Überempfindlichkeitsreaktionen. Packungen: 1 Durchstechflasche zu 120 mg Denosumab in 1.7 ml Lösung. Ausführliche Angaben entnehmen Sie bitte der Fachinformation unter www.swissmedicinfo.ch. Verkaufskategorie: A. Zulassungsinhaberin: Amgen Switzerland AG, Zug. DMO-CHE-AMG-566-2012-November-P DMO-CHE-AMG-003-2013-January-P 2. XGEVA® (Denosumab) Fachinformation, www.swissmedicinfo.ch We will discuss these topics in a pro and contra form to give recommendations for the every day practice. We intend to have a high quality scientific meeting in a special relaxing atmosphere, facilitating open and profound discussions. We will be very glad to hear your contributions to the relevant topics. On this occasion I would like to thank Dr. Maciej Kwiatkowski and Prof. Tullio Sulser for support and collaboration in preparation to this symposium. I want also to acknowledge the support of the Prostate Cancer Research Foundation. I am looking forward to see you in Zuoz With best regards AMGEN Switzerland AG Dammstrasse 21 CH-6301 Zug www.amgen.ch © 2013 AMGEN. Zug, Switzerland. Alle Rechte vorbehalten. Franz Recker PRELIMINARY PROGRAM Recommendation of the USPSTF: “the day after” and AUA Guidelines Peter Albertsen, Farmington, CT (pro) and Sigrid Carlsson, New York, NY / Göteborg (contra) Anastomosis insufficiency and fistula after primary treatment for PCa Margrit Fisch, Hamburg Update of ERSPC study at 13 years follow-up Jonas Hugosson, Göteborg Tissue selective therapies for PCa: established vs. experimental Mark Emberton, London Why risk calculators are mandatory Fritz Schröder, Rotterdam Secondary erectile dysfunction after PCa treatment – what are the options to improve the functional outcome Herbert Sperling, Mönchengladbach Quality of life and costs effectiveness of PCa screening Harry de Koning, Rotterdam PSA is Dead, Long Live PSA… and perspectives Hans Lilja, New York, NY / Malmö Hormonal therapy options in advanced PCa: intermittent vs. continuous, agonist vs. antagonist, monotherapy vs. maximal androgen blockade Peter Albertsen, Farmington, CT and Alex Zlotta, Toronto TRUS MRI Fusion in PCa imaging and diagnosis Arnauld Villers, Lille The concept and execution of the PREFERE trial Michael Stöckle, Homburg/Saar MRI in diagnosis and selection for active surveillance Laurence Klotz, Toronto Inclusion criteria in the active surveillance and trigger points for starting curative treatment Laurence Klotz, Toronto From DRE, Biopsy Analysis, Nomogram to NeuroSAFE - how to identify safely all candidates for nervesparing RP, a 20 year experience Hartwig Huland, Hamburg Quality assurance in RP: Open vs. robot assisted Peter Hammerer, Braunschweig (open), Peter Wiklund, Stockholm (robot-assisted) Bone protection and therapy of bone metastasis in PCa George Thalman, Berne Castration-resistant PCa. What are the options? What is the sequence when incorporating new treatment regimens? Silke Gillesen, St. Gallen, Lukas Manka, Braunschweig, Howard Parnes, Bethesda, MD New radionuclide treatment options in the treatment sequence of castration-resistant PCa NN Current and Future Prognostic Features in Prostate Cancer Guido Sauter, Hamburg Chemoprevention in PCa – is there life in the old dog still? Howard Parnes, Bethesda, MD Salvage lymphadenectomy in treatment of PCa Klaus-Peter Jünemann, Kiel (pro) and Markus Graefen, Hamburg (contra) New prognostic genetic markers for PCa Steven Stone, Salt Lake City, UT Radiotherapy for localized PCa: normofractionation, hypofractionation or stereotactic irradiation? Is shorter better? Thomas Wiegel, Ulm Tumor volume and grading in respect to life expectancy Theo van der Kwast, Toronto When to perform radiotherapy after radical prostatectomy: adjuvant vs. salvage vs. watchful waiting Markus Graefen, Hamburg and Thomas Wiegel, Ulm (pro and contra) Fine-mapping of the kallikrein gene region and its role in PCa aggressiveness: Results from a Canadian and ERSPC Aarau cohorts Alex Zlotta, Toronto GENERAL INFORMATION Official language: English Abstracts deadline: 31st of January, 2014 Symposium Venue: Lyceum Alpinum Zuoz Scientific meeting schedule: Thursday, the 27th of February beginning at 13.00 (official meeting start) Friday, the 28th of February beginning at 8.00 Saturday, the 1st of March beginning at 8.00 This Symposium earns 20 CME points of SGU and DGU (Swiss and German Urological Association) Social Evening: Saturday, 01. March beginning at 18.00 Optional (for early guests): “Coming together” on 26. February at 18.30 SYMPOSIUM VENUE: Lyceum Alpinum Zuoz ACCOMODATION: Castell Zuoz, Alpenschloss Hotel, CH-7524 Zuoz Tel. +41 81 851 52 53, Fax +41 81 851 52 54 www.hotelcastell.ch Posthotel Engiadina, CH-7524 Zuoz Tel. +41 81 854 10 21, Fax +41 81 854 33 03 www.hotelengiadina.ch Hotel Klarer, CH-7524 Zuoz REGISTRATION FEES AND PAYMENT Tel. +41 81 851 34 34, Fax +41 81 851 34 00 www.klarerconda.ch Participant: 500.– CHF (600.– CHF after January 15, 2014) (including social evening) Hotel Crusch Alva, CH-7524 Zuoz Accompanying person: 250.– CHF (including social evening) Cancellation fees: 100.– CHF (250.– CHF after January 15, 2014, no fee refund after February 15, 2014) Payment by bank transfer to: Prostate Cancer Symposium, Bank account No. 770526-91 IBAN CH65 0588 1077 0526 9100 0 SWIFT/BIC: AHHBCH22XXX Bank relation: Neue Aargauer Bank, 5001 Aarau, Switzerland You can preferably register and book your hotel via Symposium website: www.engadin-symposium.ch Tel. +41 81 854 13 19, Fax +41 81 854 24 59 www.hotelcruschalva.ch You are advised to make your hotel reservation as soon as possible, because of the high winter season. A limited number of rooms at reduced prices for congress participants could be arranged (first come first served basis). This contingent can be kept only until the 31st of January 2014. See registration and accomodation form for details. You can reach Zuoz / St. Moritz by railway (SBB): Zürich - Landquart - Zuoz All inquiries and abstracts are to be directed to: Dr. M. Kwiatkowski, Department of Urology Kantonsspital Aarau, CH-5001 Aarau, Switzerland E-mail: [email protected] Tel.: +41 62 838 47 47 Fax: +41 62 838 47 53 ST. MORITZ ZUOZ We want to thank: Main Sponsor: Exhibitors: Co-Sponsors: